Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment

Open access
López de Andrés, Julia, Griñán-Lisón, Carmen, Jiménez, Gema, Marchal, Juan Antonio · 2020 · Journal of Hematology & Oncology

Abstract

Cancer stem cells (CSCs) represent a tumor subpopulation responsible for tumor metastasis and resistance to chemo- and radiotherapy, ultimately leading to tumor relapse. As a consequence, the detection and eradication of this cell subpopulation represent a current challenge in oncology medicine. CSC phenotype is dependent on the tumor microenvironment (TME), which involves stem and differentiated tumor cells, as well as different cell types, such as mesenchymal stem cells, endothelial cells, fibroblasts and cells of the immune system, in addition to the extracellular matrix (ECM), different in composition to the ECM in healthy tissues. CSCs regulate multiple cancer hallmarks through the interaction with cells and ECM in their environment by secreting extracellular vesicles including exosomes, and soluble factors such as interleukins, cytokines, growth factors and other metabolites to the TME. Through these factors, CSCs generate and activate their own tumor niche by recruiting stromal cells and modulate angiogenesis, metastasis, resistance to antitumor treatments and their own maintenance by the secretion of different factors such as IL-6, VEGF and TGF-ß. Due to the strong influence of the CSC secretome on disease development, the new antitumor therapies focus on targeting these communication networks to eradicate the tumor and prevent metastasis, tumor relapse and drug resistance. This review summarizes for the first time the main components of the CSC secretome and how they mediate different tumor processes. Lastly, the relevance of the CSC secretome in the development of more precise and personalized antitumor therapies is discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-020-00966-3

Cites

Statistics

Figures

Fig. 1 Crosstalk between CSCs and TME components. CSCs secrete a wide variety of soluble factors to recruit and activate stromal cells and reorganize the ECM, as well as to promote angiogenesis, metastasis, hypoxia, immune evasion and tumor progression. These factors also regulate their own maintenance and tumor niche maintenance and the response to different anti-tumor therapies
Fig. 1 Crosstalk between CSCs and TME components. CSCs secrete a wide variety of soluble factors to recruit and activate stromal cells and reorganize the ECM, as well as to promote angiogenesis, metastasis, hypoxia, immune evasion and tumor progression. These factors also regulate their own maintenance and tumor niche maintenance and the response to different anti-tumor therapiesCC BY · PubMed Central
Fig. 2 Crosstalk between CSCs and TME cells. CSCs secrete different factors in order to recruit and activate mesenchymal stem cells (MSCs), endothelial cells (ECs), cancer-associated fibroblast (CAFs) and infiltrating immune cells (IICs) to the TME. CSCs also promote their own maintenance and are therefore able to regulate processes of hypoxia, vascularization, metastasis and immune response evasion
Fig. 2 Crosstalk between CSCs and TME cells. CSCs secrete different factors in order to recruit and activate mesenchymal stem cells (MSCs), endothelial cells (ECs), cancer-associated fibroblast (CAFs) and infiltrating immune cells (IICs) to the TME. CSCs also promote their own maintenance and are therefore able to regulate processes of hypoxia, vascularization, metastasis and immune response evasionCC BY · PubMed Central
Fig. 3 Tumor response to different antitumor strategies. The failure of conventional therapies is due to the tumor and the CSC mechanisms to initiate the carcinogenesis process. For this reason, the new therapies focus on TME, including the CSC secretome. However, CSCs use different pathways to fulfill their functions; therefore, targeting only one of the pathways can lead to tumor relapse. The new therapies are aimed at simultaneously blocking several pathways for better outcomes
Fig. 3 Tumor response to different antitumor strategies. The failure of conventional therapies is due to the tumor and the CSC mechanisms to initiate the carcinogenesis process. For this reason, the new therapies focus on TME, including the CSC secretome. However, CSCs use different pathways to fulfill their functions; therefore, targeting only one of the pathways can lead to tumor relapse. The new therapies are aimed at simultaneously blocking several pathways for better outcomesCC BY · PubMed Central
Fig. 4 Development of new personalized antitumor therapies for cancer patients. Due to the importance of CSC secretome in tumor development, chemoresistance and relapse, the new therapies need to combine different TME and CSC inhibitors. Robust biomarkers are required to identify the patients that will benefit from these treatments
Fig. 4 Development of new personalized antitumor therapies for cancer patients. Due to the importance of CSC secretome in tumor development, chemoresistance and relapse, the new therapies need to combine different TME and CSC inhibitors. Robust biomarkers are required to identify the patients that will benefit from these treatmentsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 341 · Cited by 207

Research works printed but not linked: 1

  1. Yoneura N, Takano S, Yoshitomi H, Nakata Y, Shimazaki R, Kagawa S, et al. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. Int J Mol Med. 2018;42:821–30.

Metadata

Authors
López de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A.
Affiliations
Universidad de Granada (ES)
Corresponding author
  • Jiménez, Gema
  • Marchal, Juan Antonio
Venue
Journal of Hematology & Oncology
Published
2020-10-15
Volume
13
Issue
1
Pages
136-136
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3093210528
Cited by
207
References
341
Citations by year
2026: 17 · 2025: 18 · 2024: 29 · 2023: 52 · 2022: 53 · 2021: 38
FWCI
3.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
  • Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Consejería de Salud y Familias de la Junta de Andalucía (PIN-0224-2019)
  • Ministerio de Ciencia, Innovación y Universidades (RTI2018-101309-B-C22)
  • Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (SOMM17/6109/UGR)
  • Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (PIE16/00045, DTS17/00087)
  • Chair "Doctors Galera-Requena in cancer stem cell research" (CMC-CTS963)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
cancer stem cells, secretome, tumor microenvironment, extracellular vesicles, exosomes, tumor niche, angiogenesis, metastasis, drug resistance, tumor recurrence, stromal cells, extracellular matrix, precision oncology, cytokines, vascular endothelial growth factor, TGF-beta, interleukin-6
MeSH terms
Animals, Extracellular Matrix, Humans, Interleukins, Neoplasms, Neovascularization, Pathologic, Neoplastic Stem Cells, MicroRNAs, Intercellular Signaling Peptides and Proteins, Exosomes, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. https://app.cochat.ai/papers/10.1186/s13045-020-00966-3
The paper
López de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A. (2020). Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-020-00966-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.